{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:46:11Z","timestamp":1770500771882,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T00:00:00Z","timestamp":1392595200000},"content-version":"vor","delay-in-days":4249,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1053\/joca.2001.0513","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T17:49:59Z","timestamp":1027878599000},"page":"518-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results"],"prefix":"10.1053","volume":"10","author":[{"given":"G.W.","family":"Torrance","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Raynauld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.H.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Band","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/joca.2001.0513_RF1","unstructured":"Synvisc Hylan G-F 20 US label"},{"key":"10.1053\/joca.2001.0513_RF2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/joca.2002.0798","article-title":"A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results","volume":"10","author":"Raynauld","year":"2002","journal-title":"Osteoarthritis Cart"},{"key":"10.1053\/joca.2001.0513_RF3","series-title":"Guidelines for Economic Evaluation of Pharmaceuticals: Canada","year":"1997"},{"key":"10.1053\/joca.2001.0513_RF4","series-title":"Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses","year":"1995"},{"key":"10.1053\/joca.2001.0513_RF5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1053\/joca.2001.0513_RF6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic evaluations to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"10.1053\/joca.2001.0513_RF7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/art.1780381104","article-title":"Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee","volume":"38","author":"Hochberg","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1053\/joca.2001.0513_RF8","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1053\/joca.2001.0513_RF9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey. (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1053\/joca.2001.0513_RF10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/00019053-199507060-00005","article-title":"Multi-attribute preference functions. Health utilities index","volume":"7","author":"Torrance","year":"1995","journal-title":"Pharmacoeconomics"},{"key":"10.1053\/joca.2001.0513_RF11","series-title":"Theory of Games and Economic Behaviour","author":"Von Neumann","year":"1944"},{"key":"10.1053\/joca.2001.0513_RF12","unstructured":"Statistics Canada, 1995, Consumer Price Index, January 1996 to 1998, http:\/\/www.statcan.ca\/Daily, Ottawa, Ontario, Ministry of Industry"},{"key":"10.1053\/joca.2001.0513_RF13","unstructured":"Ontario Drug Benefit Formulary\/Comparative Drug Index Edition No. 35"},{"key":"10.1053\/joca.2001.0513_RF14","unstructured":"Medis June 1998 Pharmaceuticals catalogue"},{"key":"10.1053\/joca.2001.0513_RF15","unstructured":"Ontario Schedule of Benefits"},{"key":"10.1053\/joca.2001.0513_RF16","unstructured":"Browne, G, Gafni, A, Roberts, J, Goldsmith, A, Jamieson, E, Approach to the Measurement of Costs (Expenditures) when Evaluating Health and Social Programmes"},{"key":"10.1053\/joca.2001.0513_RF17","unstructured":"Ontario Case Costing Project. 1994\/1995 & 1995\/96"},{"key":"10.1053\/joca.2001.0513_RF18","unstructured":"Statistics Canada, Average industrial aggregate"},{"key":"10.1053\/joca.2001.0513_RF19","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"1987"},{"key":"10.1053\/joca.2001.0513_RF20","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations","volume":"146","author":"Laupacis","year":"1992","journal-title":"CMAJ"},{"key":"10.1053\/joca.2001.0513_RF21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00019053-200018050-00001","article-title":"The concept of clinically meaningful difference in health-related quality of life research: how meaningful is it?","volume":"18","author":"Hays","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1053\/joca.2001.0513_RF22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0277-9536(93)90315-U","article-title":"Cost-effectiveness league tables: more harm than good?","volume":"37","author":"Drummond","year":"1993","journal-title":"Soc Sci Med"},{"key":"10.1053\/joca.2001.0513_RF23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0272989X0002000409","article-title":"A comprehensive league table of cost-utility ratios and a sub-table of \u2018panel worthy\u2019 studies","volume":"20","author":"Chapman","year":"2000","journal-title":"Med Dec Mkg"},{"key":"10.1053\/joca.2001.0513_RF24","series-title":"Cost-effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1053\/joca.2001.0513_RF25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0883-5403(94)90093-0","article-title":"Costs of elective total hip arthroplasty during the first year. Cemented versus noncemented","volume":"9","author":"Laupacis","year":"1994","journal-title":"J Arthroplasty"},{"key":"10.1053\/joca.2001.0513_RF26","unstructured":"Statistics Canada, CANSIM, Matrix 9940, Consumer price index, 1996 classification, annual health care, historical summary"},{"key":"10.1053\/joca.2001.0513_RF27","unstructured":"The Canada Customs and Revenue Agency, Average Exchange Rates for 1998"},{"key":"10.1053\/joca.2001.0513_RF28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0272989X0002000304","article-title":"Comparison of Finnish and US-based visual analog scale valuations of the EQ-5D measure","volume":"20","author":"Johnson","year":"2000","journal-title":"Med Dec Mkg"},{"key":"10.1053\/joca.2001.0513_RF29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1098-3015(11)70457-0","article-title":"The French Health Utilities Index Mark 3. Abstract","volume":"3","author":"Le Gales","year":"2000","journal-title":"Value in Health"},{"key":"10.1053\/joca.2001.0513_RF30","first-page":"S33","article-title":"A tale of two (or more) cities: geographic transferability of pharmacoeconomic data","volume":"3","author":"O'Brien","year":"1997","journal-title":"Am J Managed Care"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458401905138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458401905138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:00:56Z","timestamp":1761015656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458401905138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S1063458401905138"],"URL":"https:\/\/doi.org\/10.1053\/joca.2001.0513","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/joca.2001.0513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}